CTKB — Cytek Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1831915 ·
Last close
$5.74
Market Cap
$746.10M
52W High
$6.18
52W Low
$3.28
ADV30
1,127,489
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 48,140,000 | 28,340,000 | -11,400,000 | -12,158,000 | 446,934,000 | 73,846,000 | 124,980,000 |
| Mar 2026 | 44,135,000 | 21,254,000 | -18,463,000 | -18,866,000 | 449,113,000 | 65,665,000 | 121,469,000 |
| Dec 2025 | 62,141,000 | 32,885,000 | -5,594,000 | -44,076,000 | 461,542,000 | 90,853,000 | 119,803,000 |
| Sep 2025 | 52,293,000 | 27,551,000 | -9,192,000 | -5,478,000 | 494,919,000 | 93,281,000 | 116,348,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,039,000
Investing CF
$-2,976,000
Financing CF
$3,881,000
CapEx
$-6,133,000
Dividends Paid
—
Buybacks
$63,000
EPS Diluted TTM
$-0.62
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-132,761,000
Inventory
$52,251,000
Receivables
$51,297,000
ST Investments
$188,158,000
EBIT TTM
$-40,504,000
Pretax Income TTM
$-40,816,000
Interest Exp TTM
$312,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$206,708,992
EBITDA
$-39,761,000
Free Cash Flow
$9,295,375
Enterprise Value
$363,678,784
Total Cash
$262,004,000
Total Debt
$26,460,000
Shares Out
129,983,253
Trailing EPS
$-0.63
Book Value
$2.48
ROE
-23.0%
ROA
-6.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 201,493,000 | -40,384,000 | -66,539,000 | 461,542,000 | 119,803,000 | 341,739,000 | -4,686,000 |
| Dec 2024 | 200,453,000 | -20,523,000 | -6,020,000 | 499,500,000 | 103,763,000 | 395,737,000 | 25,379,000 |
| Dec 2023 | 193,015,000 | -27,845,000 | -12,148,000 | 494,457,000 | 101,393,000 | 393,064,000 | 5,281,000 |
| Dec 2022 | 164,036,000 | -1,804,000 | 2,576,000 | 519,476,000 | 93,930,000 | 425,295,000 | -12,231,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.07
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $5.74 · call volume: 3 · put volume: 2
Expected Move to 2026-10-16:
±$2.61
(45.56%) —
implied range
$3.12 –
$8.35
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLAB | MESA LABORATORIES INC /CO/ | $744.19M | $132.99 | — |
| APEI | AMERICAN PUBLIC EDUCATION INC | $743.41M | $40.62 | — |
| MRRDF | Meridian Mining UK Societas | $750.46M | $1.54 | — |
| BWMN | Bowman Consulting Group Ltd. | $738.59M | $42.61 | — |
| NRGV | Energy Vault Holdings, Inc. | $736.45M | $4.05 | — |
News headlines (Yahoo Finance, 1h cache)
Cytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool
2026-09-23 21:00 · Yahoo
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
2026-09-17 12:48 · Yahoo
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry
2026-09-09 12:30 · Yahoo
Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing
2026-09-09 06:37 · Yahoo
Cytek Biosciences to Participate in Upcoming Investor Conferences
2026-09-01 20:05 · Yahoo
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
2026-08-21 20:35 · Yahoo
Cytek (CTKB) Q2 2026 Earnings Call Transcript
2026-08-12 23:29 · Yahoo
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
2026-08-06 05:07 · Yahoo
Cytek Biosciences Q2 Earnings Call Highlights
2026-08-06 00:04 · Yahoo
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
2026-08-05 22:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.